infliximab-dyyb (Inflectra, Remisima, CT-P13)
Jump to navigation
Jump to search
Introduction
Biosimilar to infliximab. FDA-approved April 2016
Indications
Notes
- 2017 Medicare part D cost: $14,202/year, out of pocket $5118[2]
More general terms
References
- ↑ FDA News Release. April 5, 2016 FDA approves Inflectra, a biosimilar to Remicade http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm
- ↑ 2.0 2.1 Yazdany J, Dudley RA, Lin GA et al Out-of-Pocket Costs for Infliximab and Its Biosimilar for Rheumatoid Arthritis Under Medicare Part D. JAMA. 2018;320(9):931-933 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30193264 https://jamanetwork.com/journals/jama/fullarticle/2698912
- ↑ McKeage K. A review of CT-P13: an infliximab biosimilar. BioDrugs. 2014 Jun;28(3):313-21. Review. PMID: https://www.ncbi.nlm.nih.gov/pubmed/24723086
- ↑ 4.0 4.1 Schulze K Koppka N, Lutter F et al CT-P13 (Inflectra<T>>, Remsima<TM>) monitoring in patients with inflammatory bowel disease. Biologicals. Volume 44, Issue 5, Sept 2016, Pages 463-466 PMID: https://www.ncbi.nlm.nih.gov/pubmed/27435444
- ↑ 5.0 5.1 Meyer A, Rudant J, Drouin J et al. Effectiveness and safety of reference infliximab and biosimilar in Crohn Disease: A French equivalence study. Ann Intern Med 2018 Dec 11; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/30534946 <Internet> http://annals.org/aim/article-abstract/2718685/effectiveness-safety-reference-infliximab-biosimilar-crohn-disease-french-equivalence-study?